Regorafenib, an investigational agent for the treatment of cholangiocarcinoma. (3rd April 2021)

• Record Type: Journal Article
• Authors: Sahin, Ibrahim Halil; Tan, Elaine; Kim, Richard
• Is Part Of: Expert opinion on investigational drugs. Volume 30:Number 4(2021)
• Page Start: 333
• Page End: 341
• Publication Date: 2021-04-03
• Subjects: Cholangiocarcinoma -- biliary tumors -- regorafenib -- FGFR2 -- actionable genes -- TKIs -- targeted therapy; Drugs -- Design -- Periodicals; Drugs, Investigational -- Bibliography; Drugs, Investigational -- Periodicals; 615.1
• DOI: 10.1080/13543784.2021.1867537
• Languages: English
• ISSNs: 1354-3784

Abstract

ABSTRACT: Introduction: Cholangiocarcinoma is a prevalent gastrointestinal cancer with a high mortality rate. A limited number of cholangiocarcinoma patients are diagnosed with early-stage disease but unfortunately, most patients present with an advanced-stage disease which is not amenable to curative surgical resection. Areas Covered: We discuss regorafenib, a multi-kinase inhibitor, which has been investigated as a therapeutic agent in advanced stage biliary tract cancer patients in phase II trials. We examined the efficacy and toxicity of this agent and its potential in this patient population in the future. We also provide further insights on novel approaches to optimize the efficacy of regorafenib in cholangiocarcinoma patients. Expert Opinion: The recent phase II trials of single-agent regorafenib in advanced stage biliary tumors revealed a modest activity in non enriched patient population and is currently part of the national comprehensive cancer network (NCCN) guidelines (Level 2B) in the refractory setting. However, more opportunities for this agent exist in combination approaches with other therapeutics such as immune checkpoint inhibitors. It is also important to recognize that the paradigm has significantly shifted for targeted therapy to more specific and more potent tyrosine kinase inhibitors targeting specific actionable genes.